Literature DB >> 17917105

Modulation of ligand-gated ion channels by antidepressants and antipsychotics.

Gerhard Rammes1, Rainer Rupprecht.   

Abstract

It is generally accepted that antidepressants and antipsychotics mediate their therapeutic effects via specific interaction with processes related to synaptic neurotransmission in the central nervous system. Besides their well-known classical mechanisms of action, antidepressants and antipsychotics show widely unknown effects, which might also contribute to the pharmacological profile of these agents. There is growing evidence that an interaction of these drugs with allosteric modulatory sites of ligand-gated ion channels (LGICs) might represent a yet unknown principle of action. Such interactions of psychopharmacological drugs with LGICs might play an important role both for the therapeutic efficacy and the side effect profile of these agents. In this review, we focus on the direct interaction of antidepressants and antipsychotics with LGICs, which may provide a basis for the development of novel psychopharmacological drugs.

Mesh:

Substances:

Year:  2007        PMID: 17917105     DOI: 10.1007/s12035-007-0006-1

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  156 in total

1.  Effects of the antidepressant phenelzine on brain levels of gamma-aminobutyric acid (GABA).

Authors:  G B Baker; J T Wong; J M Yeung; R T Coutts
Journal:  J Affect Disord       Date:  1991-03       Impact factor: 4.839

2.  Clozapine inhibits synaptic transmission at GABAergic synapses established by ventral tegmental area neurones in culture.

Authors:  F J Michel; L E Trudeau
Journal:  Neuropharmacology       Date:  2000-07-10       Impact factor: 5.250

Review 3.  New insights into the role of the GABA(A)-benzodiazepine receptor in psychiatric disorder.

Authors:  D J Nutt; A L Malizia
Journal:  Br J Psychiatry       Date:  2001-11       Impact factor: 9.319

4.  Interaction of tricyclic antidepressants with the ionic channel of the acetylcholine receptor of Torpedo electric organ.

Authors:  N Shaker; A T Eldefrawi; E R Miller; M E Eldefrawi
Journal:  Mol Pharmacol       Date:  1981-11       Impact factor: 4.436

5.  Blockage of muscle and neuronal nicotinic acetylcholine receptors by fluoxetine (Prozac).

Authors:  J García-Colunga; J N Awad; R Miledi
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-04       Impact factor: 11.205

6.  Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes.

Authors:  L D Griffin; S H Mellon
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-09       Impact factor: 11.205

7.  Nicotinic acetylcholine receptor antagonistic activity of monoamine uptake blockers in rat hippocampal slices.

Authors:  E C Hennings; J P Kiss; K De Oliveira; P T Toth; E S Vizi
Journal:  J Neurochem       Date:  1999-09       Impact factor: 5.372

8.  Two types of neurone in the rat ventral tegmental area and their synaptic inputs.

Authors:  S W Johnson; R A North
Journal:  J Physiol       Date:  1992-05       Impact factor: 5.182

9.  Effects of antidepressant treatment on neuroactive steroids in major depression.

Authors:  E Romeo; A Ströhle; G Spalletta; F di Michele; B Hermann; F Holsboer; A Pasini; R Rupprecht
Journal:  Am J Psychiatry       Date:  1998-07       Impact factor: 18.112

10.  Antidepressants are functional antagonists at the serotonin type 3 (5-HT3) receptor.

Authors:  B Eisensamer; G Rammes; G Gimpl; M Shapa; U Ferrari; G Hapfelmeier; B Bondy; C Parsons; K Gilling; W Zieglgänsberger; F Holsboer; R Rupprecht
Journal:  Mol Psychiatry       Date:  2003-11       Impact factor: 15.992

View more
  12 in total

1.  RCSB Protein Data Bank: Enabling biomedical research and drug discovery.

Authors:  David S Goodsell; Christine Zardecki; Luigi Di Costanzo; Jose M Duarte; Brian P Hudson; Irina Persikova; Joan Segura; Chenghua Shao; Maria Voigt; John D Westbrook; Jasmine Y Young; Stephen K Burley
Journal:  Protein Sci       Date:  2019-11-29       Impact factor: 6.725

2.  The wake-promoting transmitter histamine preferentially enhances α-4 subunit-containing GABAA receptors.

Authors:  Matt T Bianchi; Alison G Clark; Janet L Fisher
Journal:  Neuropharmacology       Date:  2011-05-27       Impact factor: 5.250

Review 3.  Mammalian sleep genetics.

Authors:  Jessica M Kelly; Matt T Bianchi
Journal:  Neurogenetics       Date:  2012-09-14       Impact factor: 2.660

Review 4.  Rhythms and blues: modulation of oscillatory synchrony and the mechanism of action of antidepressant treatments.

Authors:  Andrew F Leuchter; Aimee M Hunter; David E Krantz; Ian A Cook
Journal:  Ann N Y Acad Sci       Date:  2015-03-23       Impact factor: 5.691

5.  Targeting ligand-gated ion channels in neurology and psychiatry: is pharmacological promiscuity an obstacle or an opportunity?

Authors:  Matt T Bianchi; Emmanuel J Botzolakis
Journal:  BMC Pharmacol       Date:  2010-03-02

6.  Low concentrations of amitriptyline inhibit nicotinic receptors in unmyelinated axons of human peripheral nerve.

Authors:  A Freysoldt; J Fleckenstein; P M Lang; D Irnich; P Grafe; R W Carr
Journal:  Br J Pharmacol       Date:  2009-08-19       Impact factor: 8.739

7.  The antidepressant bupropion is a negative allosteric modulator of serotonin type 3A receptors.

Authors:  Akash Pandhare; Aneesh Satya Pappu; Henrik Wilms; Michael Paul Blanton; Michaela Jansen
Journal:  Neuropharmacology       Date:  2016-09-24       Impact factor: 5.250

8.  Antidepressant drugs transactivate TrkB neurotrophin receptors in the adult rodent brain independently of BDNF and monoamine transporter blockade.

Authors:  Tomi Rantamäki; Liisa Vesa; Hanna Antila; Antonio Di Lieto; Päivi Tammela; Angelika Schmitt; Klaus-Peter Lesch; Maribel Rios; Eero Castrén
Journal:  PLoS One       Date:  2011-06-07       Impact factor: 3.240

9.  Clinical pharmacology in sleep medicine.

Authors:  Ashley Proctor; Matt T Bianchi
Journal:  ISRN Pharmacol       Date:  2012-11-14

10.  Identification of a domain which affects kinetics and antagonistic potency of clozapine at 5-HT3 receptors.

Authors:  Gerhard Rammes; Christine Hosp; Brigitte Eisensamer; Sascha Tanasic; Caroline Nothdurfter; Walter Zieglgänsberger; Rainer Rupprecht
Journal:  PLoS One       Date:  2009-08-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.